Tonix Pharmaceuticals Holding Corp. SEC filings document a commercial-stage biotechnology company with Nasdaq-listed common stock and programs spanning CNS disorders, immunology, infectious diseases and rare diseases. Recent Form 8-K reports cover Regulation FD disclosures, selected operating and financial results, capital-structure information, commercial arrangements for TONMYA, and clinical or preclinical updates for programs such as TNX-4800, TNX-1700 and TNX-1900.
The company’s proxy and annual meeting filings describe board elections, shareholder voting results, equity incentive plan approvals, executive compensation matters and other governance subjects. Tonix filings also provide formal records of material events, exhibit-based press releases and presentations, risk-related disclosures, registered securities and public-company reporting obligations.
Tonix Pharmaceuticals Holding Corp. (TNXP) is the subject of an amended ownership report in which AQR Capital Management, LLC and its parent, AQR Capital Management Holdings, LLC, each reported beneficial ownership of 670,805 common shares, or 3.91%, as of September 30, 2026. The schedule identifies the reported ownership as 5% or less.
Tonix Pharmaceuticals Holding Corp. (TNXP) Chief Executive Officer Seth Lederman purchased 5,000 common shares at $4.055 per share on November 11, 2026. His directly held position afterward was 16,005 shares. Reported indirect positions include 20,001 shares through an IRA account and 1 share through Lederman & Co.; a footnote says Lederman may be deemed a control person of the entity.
Tonix Pharmaceuticals Holding Corp. (TNXP) reported product revenue of $17.234 million for the three months ended September 30, 2026, versus $3.290 million a year earlier, primarily reflecting TONMYA sales after its November 2025 launch; TONMYA generated $15.024 million. Nine-month product revenue was $37.656 million versus $7.717 million. Net loss was $53.329 million for the quarter and $134.075 million for nine months, compared with $32.010 million and $77.111 million, respectively, in 2025.
Cash and cash equivalents were $162.793 million as of September 30, 2026. Operating cash use totaled $125.635 million for nine months. The company sold 6.3 million shares under its 2025 at-the-market program for $81.7 million in net proceeds over nine months, then raised $1.5 million net from subsequent sales. Management said it believes cash and subsequent proceeds will fund planned operating and capital spending into early third quarter 2027, but not 12 months from issuance; it said these conditions raise substantial doubt about continuing as a going concern and that further funding is needed. A Phase 2 MDD study is enrolling; a TNX-4800 Phase 2 study is planned for first quarter 2027, pending final FDA review and agreement on the study protocol.
Tonix Pharmaceuticals Holding Corp. (TNXP) reported third-quarter 2026 net product revenue of $17.234 million, compared with $3.290 million in the same 2025 quarter. TONMYA net sales were approximately $15.0 million, up 37% from the second quarter.
Net loss available to common stockholders was $53.329 million, or $2.89 per share, compared with $32.010 million, or $3.59 per share, in third-quarter 2025. Research and development expenses were $25.824 million versus $9.289 million; selling, general and administrative expenses were $45.590 million versus $25.701 million. Net cash used in operating activities for the nine months ended September 30, 2026, was approximately $125.6 million, versus $60.2 million in the same 2025 period.
Cash and cash equivalents were $162.793 million as of September 30, 2026, versus $207.637 million as of December 31, 2025. Tonix believes its cash resources as of September 30, 2026, together with approximately $1.5 million in net proceeds from equity offerings after that date, will meet operating and capital expenditure requirements into early third quarter 2027. The adaptive Phase 2 TRAIL field study of TNX-4800 is expected to begin in the first quarter of 2027, pending final FDA agreement on the protocol.
Tonix Pharmaceuticals Holding Corp. (TNXP) disclosed preliminary estimates for the three months ended September 30, 2026, including TONMYA net revenue of $14.0 million to $15.0 million. Estimated cash and cash equivalents were approximately $162.8 million as of September 30, 2026.
The company has not completed its financial closing procedures. The estimates are subject to completion and revision, and actual results could be materially different.
Tonix Pharmaceuticals Holding Corp. (TNXP) reported a new agreement with a pharmacy benefit manager, effective immediately, that provides TONMYA coverage to approximately 21 million Medicare Part D beneficiaries. This second major managed Medicare agreement raises TONMYA’s Medicare coverage to 32 million lives, or 58% of roughly 55 million Medicare lives in the U.S.
Total commercial and government payer coverage for TONMYA now reaches about 166 million covered lives, representing 53% of approximately 314 million total U.S. lives. Tonix highlighted TONMYA as the first new prescription medicine approved for fibromyalgia in more than 15 years, with U.S. patents expected to provide market exclusivity until 2034, and noted that its sales force has expanded to 150 representatives to support the product launch.
Tonix Pharmaceuticals Holding Corp. (TNXP) announced the promotion of Thomas Englese, MBA, to Chief Commercial Officer, effective September 8, 2026. He has led Tonix’s commercial organization and the U.S. launch of TONMYA, and will continue overseeing sales, marketing, market access, and commercial operations for TONMYA and the acute migraine products Zembrace SymTouch and Tosymra.
The disclosure also reiterates the approved indication, contraindications, major warnings, and adverse reactions for TONMYA, including risks related to pregnancy, serotonin syndrome with concomitant serotonergic drugs, CNS depression, tricyclic antidepressant-like effects, and specific considerations for hepatic impairment, lactation, pediatric, and geriatric use.
Tonix Pharmaceuticals Holding Corp. (TNXP) reported the initial beneficial ownership of its Chief Commercial Officer, Thomas Englese, on a Form 3. He holds 694 shares of common stock directly and several stock options covering 500, 6,500, 12,480 and 40,000 underlying common shares, with exercise prices between $8.05 and $20.18 and expirations from September 9, 2034 to February 24, 2036. Footnotes state these options were granted under Tonix’s Amended and Restated 2020 Stock Incentive Plan and vest over three- or four-year schedules starting on each grant’s first anniversary.